I am a healthcare professional in the UK
I am a patient or member of the public
ECIL-10 recommendations for managing post-transplant CMV, including refractory and resistant cases
ECIL-10 recommendations for managing post-transplant CMV, including refractory and resistant cases
This infographic summarises key ECIL10 recommendations for assessing, preventing, and managing CMV in adult allogeneic HSCT recipients, including guidance for refractory and resistant cases. It provides a clear overview of current expert consensus on monitoring, prophylaxis, preemptive therapy, and treatment selection to support clinical decision making in high risk transplant patients.
/
You might be interested in
1 minute
download
This concise guide to LIVTENCITY® (maribavir) is designed for clarity and ease of use. It summarises key insights from the Phase 3 SOLSTICE trial, including efficacy outcomes, safety data, and practical dosing guidance.
article
6 minutes
A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article
5 minutes
Key efficacy outcomes from clinical trials evaluating LIVTENCITY in patients with post-transplant CMV, including virologic response and treatment comparisons.
article
3 minutes
CMV is one of the most common infections experienced by transplant recipients
article
4 minutes
An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.
